CN116999394A - 一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法 - Google Patents
一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法 Download PDFInfo
- Publication number
- CN116999394A CN116999394A CN202310983395.0A CN202310983395A CN116999394A CN 116999394 A CN116999394 A CN 116999394A CN 202310983395 A CN202310983395 A CN 202310983395A CN 116999394 A CN116999394 A CN 116999394A
- Authority
- CN
- China
- Prior art keywords
- liquid medicine
- mrna
- patient
- skin
- proper amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011148 porous material Substances 0.000 title claims abstract description 34
- 238000002659 cell therapy Methods 0.000 title claims abstract description 16
- 238000005282 brightening Methods 0.000 title claims abstract description 12
- 108020004999 messenger RNA Proteins 0.000 title claims abstract 11
- 239000007788 liquid Substances 0.000 claims abstract description 49
- 210000003491 skin Anatomy 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 42
- 239000002502 liposome Substances 0.000 claims abstract description 32
- 108010035532 Collagen Proteins 0.000 claims abstract description 19
- 238000004140 cleaning Methods 0.000 claims abstract description 18
- 239000003102 growth factor Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 9
- 210000002615 epidermis Anatomy 0.000 claims abstract description 8
- 239000000645 desinfectant Substances 0.000 claims abstract description 6
- 230000000249 desinfective effect Effects 0.000 claims abstract description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 12
- 238000009210 therapy by ultrasound Methods 0.000 claims description 12
- 230000010261 cell growth Effects 0.000 claims description 11
- 235000012000 cholesterol Nutrition 0.000 claims description 11
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 125000002091 cationic group Chemical group 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims description 5
- 102100029136 Collagen alpha-1(II) chain Human genes 0.000 claims description 5
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 claims description 5
- 102100033825 Collagen alpha-1(XI) chain Human genes 0.000 claims description 5
- 102100037285 Collagen alpha-1(XXIV) chain Human genes 0.000 claims description 5
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims description 5
- 102100031502 Collagen alpha-2(V) chain Human genes 0.000 claims description 5
- 102100031501 Collagen alpha-3(V) chain Human genes 0.000 claims description 5
- 101000771163 Homo sapiens Collagen alpha-1(II) chain Proteins 0.000 claims description 5
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 claims description 5
- 101000710623 Homo sapiens Collagen alpha-1(XI) chain Proteins 0.000 claims description 5
- 101000952969 Homo sapiens Collagen alpha-1(XXIV) chain Proteins 0.000 claims description 5
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims description 5
- 101000941594 Homo sapiens Collagen alpha-2(V) chain Proteins 0.000 claims description 5
- 101000941596 Homo sapiens Collagen alpha-3(V) chain Proteins 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 102000007327 Protamines Human genes 0.000 claims description 5
- 108010007568 Protamines Proteins 0.000 claims description 5
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 229940048914 protamine Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- -1 COL11A3 Proteins 0.000 claims description 2
- 102100033885 Collagen alpha-2(XI) chain Human genes 0.000 claims description 2
- 101000710619 Homo sapiens Collagen alpha-2(XI) chain Proteins 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 abstract description 3
- 229920001436 collagen Polymers 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及生物工程技术领域，并公开了一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，包括如下步骤，步骤S1，表面清洁，使用碘伏消毒液对患者的待治疗区域进行清理消毒；步骤S2，使用滚轮微针对步骤S1患者待治疗区域进行表皮层刺穿；步骤S3，使用纳米微针向步骤S2患者的皮下注射适量药液A，药液A为载生长因子脂质体；步骤S4，使用纳米微针向步骤S3患者的皮内注射适量药液B，药液B为载胶原蛋白基因编码的mRNA的脂质体；步骤S5，定期对治疗区域进行清洁，本发明可以促进患者治疗区域胶原蛋白的编码和释放过程，从而使治疗区域的毛孔细化同时具有提亮肤色的功能。
Description
技术领域
本发明涉及生物工程技术领域，更具体地说，涉及一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法。
背景技术
毛孔粗大的诱发因素包括外源性及内源性因素，如性别、遗传易感性、老化、慢性紫外线曝光、外源性刺激物质、痤疮、脂溢性皮炎等。毛孔粗大是因为毛孔体积增大，在聚焦激光显微镜下毛孔表现为表皮增长并延伸刺入真皮内，真皮乳头层上升到表皮层面，形成镜下的“钟乳石样外观”表现。造成肉眼上见到皮肤质地不平整及凹陷样外观，目前认为造成面部毛孔粗大的主要成因为皮脂腺分泌旺盛、毛孔周围组织结构弹性松弛、毛囊肥大。有研究指出皮脂腺分泌与毛孔大小存在正相关性。激素水平为皮脂腺分泌的重要调节因子，孕激素上调可能激活皮脂腺分泌皮脂分泌旺盛与毛孔粗大的密切关系。另外，毛孔大小与年龄老化有关，皮肤弹性下降造成皮肤完整性减退，毛囊周围支持结构松弛可造成毛孔粗大的外观改变。还有，既往严重痤疮可能导致毛囊翘的微小瘢痕形成，在雄激素刺激下可发生毛囊翘阻塞，导致毛囊体积增大、毛孔增粗。
目前针对改善毛孔粗大的治疗手段主要以光电治疗为主，常见的有半导体激光、剥脱及非剥脱点阵激光、微针射频等。光电治疗是通过光热作用原理刺激皮肤组织胶原蛋白变性、再生，可获得改善毛孔粗大的效果，但这种光热效应可能带来严重的水泡、色素沉着等术后症状，化妆品作为一种温和的起到美化或改变外表而用于人体皮肤的护理产品，受到了大众的青睐。现有的化妆品主要通过物理的方式应对毛孔粗大，比如使用聚甲基丙烯酸甲酯、硅石、尼龙12、改性淀粉等吸油粉末吸附过度分泌的油脂。另外还可以通过涂抹粉底液等彩妆产品，起到对毛孔的遮盖、柔焦、填充效果，但这些都不能从根本上改变毛孔粗大的事实，为此，本申请提出了一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法。
发明内容
本发明的目的是针对现有技术的不足，提供一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法。
本发明的上述技术目的是通过以下技术方案得以实现的：一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，包括如下步骤：
步骤S1，表面清洁，使用碘伏消毒液对患者的待治疗区域进行清理消毒；
步骤S2，使用滚轮微针对步骤S1患者待治疗区域进行表皮层刺穿；
步骤S3，使用纳米微针向步骤S2患者的皮下注射适量药液A，药液A为载生长因子脂质体；
步骤S4，使用纳米微针向步骤S3患者的皮内注射适量药液B，药液B为载胶原蛋白基因编码的mRNA的脂质体；
步骤S5，定期对治疗区域进行清洁。
作为优选的，所述步骤S2滚轮微针的针直径为0.07—0.2mm，针长为1.5—2.0mm。
作为优选的，所述步骤S3的药液A为适量生理盐水和细胞生长因子组成的混合液，所述细胞生长因子为白细胞介素2，所述药液A具体制备过程如下：
取白细胞介素2m l，放入10m l容量瓶加入0.9％NaC l溶液搅拌混合。
作为优选的，所述步骤S4药液B的制备过程如下，
采用薄膜分散法，称取质量比为(1-3):1的阳离子脂质体DOTAP与胆固醇，加入圆底晒平中并加入适量的三氯甲烷，30℃旋蒸至瓶底形成一层脂质体薄膜，真空干燥2h除去有机溶剂，加入适量去离子水，超声波处理30min，再取含有胶原蛋白基因编码的mRNA溶液并加入等质量的透明质酸溶液混合，室温静置10min，再与鱼精蛋白以体积比1:1进行混合，静置10min，得药液B。
作为优选的，所述步骤S2的胶原蛋白基因编码包括COL1A1、COL1A2、COL2A1、COL3A1、COL5A1、COL5A2、COL5A3、COL11A1、COL11A2、COL11A3、COL24A1。
作为优选的，所述阳离子脂质体DOTAP与胆固醇的比例为3:1，且超声波处理按照其他物质与脂质体质量比1:5进行配比，超声处理为70min。
本发明所述方案相比于现有技术的有益效果如下：
本发明通过滚轮微针对治疗区域进行刺穿，一方面使用特制无针头微针将小分子盐水(生理盐水)直接输送到皮下，通过水液的软性剥离能力，把皮肤逐层分开，破坏衰老迟缓黑色素富集的老年细胞在皮下形成微创面，刺激人体的自愈自我修复功能配合特殊调配的营养修复液，促使细胞再生分裂，不断产生新的细胞和修复物质，皮下创伤愈合过程中会产生组织再生，其中还加入了可以促进细胞进行蛋白质合成过程的细胞生长因子白细胞介素2，从而促进治疗区域的组织重组修复，另一方面，通过向患者皮肤内注射药液B即载胶原蛋白基因编码的mRNA的脂质体，促进患者治疗区域胶原蛋白的编码和释放过程，从而使治疗区域的毛孔细化同时具有提亮肤色的功能。
具体实施方式
下面通过具体实施例对发明做进一步详述，以下实施例只是描述性的，不是限定性的本发明的保护范围。
实施例1
一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，包括如下步骤：
步骤S1，表面清洁，使用碘伏消毒液对患者的待治疗区域进行清理消毒；
步骤S2，使用滚轮微针对步骤S1患者待治疗区域进行表皮层刺穿；
步骤S3，使用纳米微针向步骤S2患者的皮下注射适量药液A，药液A为载生长因子脂质体；
步骤S4，使用纳米微针向步骤S3患者的皮内注射适量药液B，药液B为载胶原蛋白基因编码的mRNA的脂质体；
步骤S5，定期对治疗区域进行清洁。
本实施例中，步骤S2滚轮微针的针直径为0.07—0.2mm，针长为1.5—2.0mm，步骤S3的药液A为适量生理盐水和细胞生长因子组成的混合液，所述细胞生长因子为白细胞介素2，所述药液A具体制备过程如下：
取白细胞介素2m l，放入10m l容量瓶加入0.9％NaC l溶液搅拌混合，步骤S4药液B的制备过程如下，
采用薄膜分散法，称取质量比为1:1的阳离子脂质体DOTAP与胆固醇，加入圆底晒平中并加入适量的三氯甲烷，30℃旋蒸至瓶底形成一层脂质体薄膜，真空干燥2h除去有机溶剂，加入适量去离子水，超声波处理30min，再取含有胶原蛋白基因编码的mRNA溶液并加入等质量的透明质酸溶液混合，室温静置10min，再与鱼精蛋白以体积比1:1进行混合，静置10min，得药液B，步骤S2的胶原蛋白基因编码包括COL1A1、COL1A2、COL2A1、COL3A1、COL5A1、COL5A2、COL5A3、COL11A1、COL11A2、COL11A3、COL24A1，阳离子脂质体DOTAP与胆固醇的比例为3:1，且超声波处理按照其他物质与脂质体质量比1:5进行配比，超声处理为70min。
实施例2
一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，包括如下步骤：
步骤S1，表面清洁，使用碘伏消毒液对患者的待治疗区域进行清理消毒；
步骤S2，使用滚轮微针对步骤S1患者待治疗区域进行表皮层刺穿；
步骤S3，使用纳米微针向步骤S2患者的皮下注射适量药液A，药液A为载生长因子脂质体；
步骤S4，使用纳米微针向步骤S3患者的皮内注射适量药液B，药液B为载胶原蛋白基因编码的mRNA的脂质体；
步骤S5，定期对治疗区域进行清洁。
本实施例中，步骤S2滚轮微针的针直径为0.07—0.2mm，针长为1.5—2.0mm，步骤S3的药液A为适量生理盐水和细胞生长因子组成的混合液，所述细胞生长因子为白细胞介素2，所述药液A具体制备过程如下：
取白细胞介素2m l，放入10m l容量瓶加入0.9％NaC l溶液搅拌混合，步骤S4药液B的制备过程如下，
采用薄膜分散法，称取质量比为2:1的阳离子脂质体DOTAP与胆固醇，加入圆底晒平中并加入适量的三氯甲烷，30℃旋蒸至瓶底形成一层脂质体薄膜，真空干燥2h除去有机溶剂，加入适量去离子水，超声波处理30min，再取含有胶原蛋白基因编码的mRNA溶液并加入等质量的透明质酸溶液混合，室温静置10min，再与鱼精蛋白以体积比1:1进行混合，静置10min，得药液B，步骤S2的胶原蛋白基因编码包括COL1A1、COL1A2、COL2A1、COL3A1、COL5A1、COL5A2、COL5A3、COL11A1、COL11A2、COL11A3、COL24A1，阳离子脂质体DOTAP与胆固醇的比例为3:1，且超声波处理按照其他物质与脂质体质量比1:5进行配比，超声处理为70min。
实施例3
一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，包括如下步骤：
步骤S1，表面清洁，使用碘伏消毒液对患者的待治疗区域进行清理消毒；
步骤S2，使用滚轮微针对步骤S1患者待治疗区域进行表皮层刺穿；
步骤S3，使用纳米微针向步骤S2患者的皮下注射适量药液A，药液A为载生长因子脂质体；
步骤S4，使用纳米微针向步骤S3患者的皮内注射适量药液B，药液B为载胶原蛋白基因编码的mRNA的脂质体；
步骤S5，定期对治疗区域进行清洁。
本实施例中，步骤S2滚轮微针的针直径为0.07—0.2mm，针长为1.5—2.0mm，步骤S3的药液A为适量生理盐水和细胞生长因子组成的混合液，所述细胞生长因子为白细胞介素2，所述药液A具体制备过程如下：
取白细胞介素2m l，放入10m l容量瓶加入0.9％NaC l溶液搅拌混合，步骤S4药液B的制备过程如下，
采用薄膜分散法，称取质量比为3:1的阳离子脂质体DOTAP与胆固醇，加入圆底晒平中并加入适量的三氯甲烷，30℃旋蒸至瓶底形成一层脂质体薄膜，真空干燥2h除去有机溶剂，加入适量去离子水，超声波处理30min，再取含有胶原蛋白基因编码的mRNA溶液并加入等质量的透明质酸溶液混合，室温静置10min，再与鱼精蛋白以体积比1:1进行混合，静置10min，得药液B，步骤S2的胶原蛋白基因编码包括COL1A1、COL1A2、COL2A1、COL3A1、COL5A1、COL5A2、COL5A3、COL11A1、COL11A2、COL11A3、COL24A1，阳离子脂质体DOTAP与胆固醇的比例为3:1，且超声波处理按照其他物质与脂质体质量比1:5进行配比，超声处理为70min。
本具体实施例仅仅是对本发明的解释，其并不是对本发明的限制，本领域技术人员在阅读完本说明书后可以根据需要对本实施条例作出没有创造性贡献的修改，但只要在本发明的权利要求范围内都受到专利法的保护。
Claims (6)
1.一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，其特征在于，包括如下步骤：
步骤S1，表面清洁，使用碘伏消毒液对患者的待治疗区域进行清理消毒；
步骤S2，使用滚轮微针对步骤S1患者待治疗区域进行表皮层刺穿；
步骤S3，使用纳米微针向步骤S2患者的皮下注射适量药液A，药液A为载生长因子脂质体；
步骤S4，使用纳米微针向步骤S3患者的皮内注射适量药液B，药液B为载胶原蛋白基因编码的mRNA的脂质体；
步骤S5，定期对治疗区域进行清洁。
2.根据权利要求1所述的一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，其特征在于，所述步骤S2滚轮微针的针直径为0.07—0.2mm，针长为1.5—2.0mm。
3.根据权利要求1所述的一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，其特征在于，所述步骤S3的药液A为适量生理盐水和细胞生长因子组成的混合液，所述细胞生长因子为白细胞介素2，所述药液A具体制备过程如下：
取白细胞介素2ml，放入10ml容量瓶加入0.9％NaCl溶液搅拌混合。
4.根据权利要求1所述的一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，其特征在于，所述步骤S4药液B的制备过程如下，
采用薄膜分散法，称取质量比为(1-3):1的阳离子脂质体DOTAP与胆固醇，加入圆底晒平中并加入适量的三氯甲烷，30℃旋蒸至瓶底形成一层脂质体薄膜，真空干燥2h除去有机溶剂，加入适量去离子水，超声波处理30min，再取含有胶原蛋白基因编码的mRNA溶液并加入等质量的透明质酸溶液混合，室温静置10min，再与鱼精蛋白以体积比1:1进行混合，静置10min，得药液B。
5.根据权利要求1所述的一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，其特征在于，所述步骤S2的胶原蛋白基因编码包括COL1A1、COL1A2、COL2A1、COL3A1、COL5A1、COL5A2、COL5A3、COL11A1、COL11A2、COL11A3、COL24A1。
6.根据权利要求4所述的一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法，其特征在于，所述阳离子脂质体DOTAP与胆固醇的比例为3:1，且超声波处理按照其他物质与脂质体质量比1:5进行配比，超声处理为70min。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310983395.0A CN116999394A (zh) | 2023-08-07 | 2023-08-07 | 一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310983395.0A CN116999394A (zh) | 2023-08-07 | 2023-08-07 | 一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116999394A true CN116999394A (zh) | 2023-11-07 |
Family
ID=88572304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310983395.0A Pending CN116999394A (zh) | 2023-08-07 | 2023-08-07 | 一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116999394A (zh) |
-
2023
- 2023-08-07 CN CN202310983395.0A patent/CN116999394A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Friedmann et al. | Combination of intense pulsed light, Sculptra, and Ultherapy for treatment of the aging face. | |
| WO2017186046A1 (zh) | 一种皮肤促渗方法及其促渗剂 | |
| Herman et al. | Skin care during the menopause period: noninvasive procedures of beauty studies | |
| JP2016527338A (ja) | ヒアルロン酸の架橋方法；注射用ハイドロゲルの調製方法；得られるハイドロゲル；得られるハイドロゲルの使用 | |
| CN111110623A (zh) | 自体修复小小针营养液配方 | |
| WO2011044367A1 (en) | Methods and compositions for skin regeneration | |
| EP2510980A1 (en) | A method for the dermocosmetic treatment of skin by application of NGF-containing compositions | |
| CN109044907A (zh) | 一种无痛透皮美容微针贴及其制备方法 | |
| RU2383341C2 (ru) | Способ омоложения кожи | |
| CN104815398A (zh) | 结合微针贴的光子嫩肤系统 | |
| CN104921961A (zh) | 一种多效修复的可降解生物微针贴 | |
| CN110859794A (zh) | 一种外泌体经皮递送制剂及其用途 | |
| US20180099140A1 (en) | Method and system for triggering wound recovery by delivering solution into the pores of recipient | |
| WO2015107237A1 (es) | Formulación cosmética de uso tópico con capacidad de regeneración dérmica, epidérmica y antiarrugas | |
| CN110711150B (zh) | 一种多肽脂质体的制备方法及其应用 | |
| CN116999394A (zh) | 一种用于改善皮肤毛孔粗大提亮肤色的mRNA活性细胞疗法 | |
| KR101917026B1 (ko) | 피부 주름 개선 또는 예방용 화장료 조성물 | |
| CN215135863U (zh) | 微电流纳米微针晶片装置 | |
| CN116919881A (zh) | 一种基于mRNA活性细胞的毛孔改善提亮肤色方法 | |
| RU2611397C1 (ru) | Способ регенерации и омоложения кожи (варианты) | |
| RU2389516C2 (ru) | Способ радиочастотного двухэтапного ремоделирования атрофической кожи лица и тела | |
| Lee et al. | Advancements in Skin‐Mediated Drug Delivery: Mechanisms, Techniques, and Applications | |
| Santos et al. | Auxilary Procedures | |
| CN116712569A (zh) | 一种通过改变腺嘌呤核苷酸转运体mRNA的表达提亮肤色且提高毛孔粗大治疗效果的方法 | |
| CN116726205A (zh) | 一种促进毛孔恢复提亮肤色的mRNA活性细胞液配置方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |